“The third quarter of 2025 marked another quarter of significant execution as we reported positive topline results from our Phase 2 Avail trial of once-weekly canvuparatide,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences (MBX). “These strong results support our belief that canvuparatide has the potential to be best-in-class in hypoparathyroidism, an estimated multibillion dollar market. We are preparing for meetings with US and EU regulatory agencies, initiation of our Phase 3 trial and future commercialization. With a clinically validated PEP(TM) platform, and cash runway into 2029, MBX is well positioned to execute on our value-creating milestones in 2026 across our pipeline and become a leading, fully integrated endocrine and metabolic disease biopharma company.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- DraftKings, Flutter downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 11/4/2025, According to Top Analysts
- Buy Rating for MBX Biosciences Driven by Promising PEP Platform and Successful Phase II Trials
- MBX Biosciences initiated with a Buy at TD Cowen
- MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide